North Carolina is currently home to 2737 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Winston-Salem, Charlotte and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
Recruiting
This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (steatohepatitis) as well as fibrosis in subjects with non alcoholic steatohepatitis (NASH). as well as the safety and tolerability of AXA1125. Subjects will take one of two different doses of AXA1125 or a placebo twice daily, and a liver biopsy will be done at the beginning and end of the 48-week study.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: Lucas Research - Diabetes & Endocrinology Consultants, PC, Morehead City, North Carolina
Conditions: Non Alcoholic Steatohepatitis (NASH)
Electron Beam Intraoperative Radiation Therapy Following Chemoradiation in Patients With Pancreatic Cancer With Vascular Involvement
Recruiting
This research study is studying an intervention as a possible treatment for pancreatic cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: University of North, Carolina Chapel Hill, Chapel Hill, North Carolina
Conditions: Pancreas Cancer
CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome
Recruiting
A Phase 2b study looks at the safety and efficacy of a treatment that is being investigated for people with certain diseases. This study will be conducted at multiple centers in the United States where participants with Gorlin Syndrome, also known as basal cell nevus syndrome, will be randomly placed into two groups; one group will receive the active topical gel, the other a topical vehicle gel, also know as placebo. Participants will apply this topical product to their face once a day for 6 mon... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/26/2022
Locations: Duke University, Durham, North Carolina
Conditions: BCCs in Gorlin Syndrome Patients
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy. Condition or disease: Breast Cancer Intervention/treatment: Drug: Gedatolisib Drug: Palbociclib Drug: Fulvestrant Drug: Alpelisib Phase 3
Gender:
All
Ages:
18 years and above
Trial Updated:
08/02/2022
Locations: Cone Health Cancer Center at Alamance Regional, Hematology/Oncology, Greensboro, North Carolina
Conditions: Breast Cancer
Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults
Recruiting
This study evaluates an investigational vaccine that is designed to protect humans against infection with SARS-CoV-2, the novel coronavirus causing COVID-19 disease. The investigational vaccine, MV-014-212, is a live attenuated vaccine against respiratory syncytial virus (RSV) that is expressing the spike (S) protein of SARS-CoV-2. MV-014-212 is administered as drops or a spray in the nose. Specifically, this study analyzes the safety of, and the immune response to, the vaccine when administered... Read More
Gender:
All
Ages:
Between 18 years and 69 years
Trial Updated:
08/01/2022
Locations: Wake Research, Raleigh, North Carolina
Conditions: Covid19
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Recruiting
To evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of radiographic progression-free survival (rPFS) in mCRPC subjects unselected for deoxyribonucleic acid (DNA) damage repair deficiencies (DRD) status (Cohort 1) to evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of rPFS in mCRPC subjects harboring DRD (Cohort 2).
Gender:
Male
Ages:
18 years and above
Trial Updated:
07/28/2022
Locations: Messino Cancer Centers, Asheville, North Carolina
Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
USCRI Ready4Life Program
Recruiting
The U.S. Committee for Refugees and Immigrants (USCRI) has developed the Relationships, Education, Advancement, and Development for Youth for Life (READY4Life) Program. This is a 16-hour program for immigrants/refugees, ages 14 to 24. The program is designed to help young immigrants and refugees prepare for a successful life in the United States. The program is taught by USCRI program staff and is being implemented at eight sites across the U.S.: Cleveland, Ohio; Colchester, Vermont; Des Moines,... Read More
Gender:
All
Ages:
Between 14 years and 18 years
Trial Updated:
07/25/2022
Locations: USCRI North Carolina, Raleigh, North Carolina
Conditions: Communication, Problem Solving, Social Relationships, Economic Stability
Comparing Meniscal Repair Biologic Augmentation: Marrow Venting Procedure Versus PRP (MVP Trial)
Recruiting
There are no current or past RCT comparing biologic augments for meniscal repair. There is good data supporting both the use of BMVP of the intercondylar notch and intra-articular PRP injections for augmentation of meniscal repair. However, the effectiveness of these augmentation methods with respect to each other has never been investigated. The knowledge gained will allow us to potentially influence and adapt protocols to treat this particular patient population. Additionally, resources availa... Read More
Gender:
All
Ages:
16 years and above
Trial Updated:
07/11/2022
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: Meniscal Tear
Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis
Recruiting
The primary objective of this study was to determine the ability of cardiac magnetic resonance (CMR) to identify cardiac involvement in patients with sarcoidosis. Patients were to undergo CMR in addition to routine clinical evaluation.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/29/2022
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Sarcoidosis
R21: An Easy-to-use, iNtelligent, Affordable LinEr (ENABLE) System for Socket Fit Assessment
Recruiting
Lower limb amputees (LLA) rely on their prosthetic legs to remain active and lead an independent life. For most LLAs, a well-fitted prosthetic socket is the only option to interface with their prosthetic leg, however, it is a real challenge to make a prosthetic socket to interface with residual limbs accurately. One of the reasons is that there lack of accurate approaches to evaluate the pressure distribution on the residual limb accurately and effectively. To overcome this issue, the research t... Read More
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
06/28/2022
Locations: NC State University, Raleigh, North Carolina
Conditions: Lower Limb Amputation Below Knee (Injury)
CSD201203: A Study to Determine Subject Puffing Patterns of a Non-cylindrical, Closed, Electronic Nicotine Delivery System at Three Nicotine Concentrations in an Ambulatory Setting
Recruiting
This is a multi-center, open-label, parallel, three-study-group investigation to evaluate the puffing patterns of healthy adult consumers of tobacco products switching from a usual brand (UB) Electronic Nicotine Delivery Systems (ENDS) product to the ENDS Investigational Product (IP), over a 9-day ambulatory period.
Gender:
All
Ages:
21 years and above
Trial Updated:
06/23/2022
Locations: Accellacare Hickory, Hickory, North Carolina
Conditions: Smoking, Tobacco Use, Electronic Cigarette Use
Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy
Recruiting
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab and rituximab plus chemotherapy or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.
Gender:
All
Ages:
All
Trial Updated:
06/23/2022
Locations: University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center (Adults and Pediatrics), Chapel Hill, North Carolina
Conditions: Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications